Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 187

1.

Inclusion of pregnant women in antiretroviral drug research: what is needed to move forwards?

Fairlie L, Waitt C, Lockman S, Moorhouse M, Abrams EJ, Clayden P, Boffito M, Khoo S, Rees H, Cournil A, Venter WF, Serenata C, Chersich M.

J Int AIDS Soc. 2019 Sep;22(9):e25372. doi: 10.1002/jia2.25372.

PMID:
31529598
2.

Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a 2-Drug Antiretroviral Therapy for HIV-1 Infection.

Boffito M, Waters L, Cahn P, Paredes R, Koteff J, van Wyk J, Vincent T, Demarest J, Adkison K, Quercia R.

AIDS Res Hum Retroviruses. 2019 Sep 11. doi: 10.1089/AID.2019.0171. [Epub ahead of print]

PMID:
31507204
3.

Improved Central Nervous System Symptoms in People with HIV without Objective Neuropsychiatric Complaints Switching from Efavirenz to Rilpivirine Containing cART.

Vera JH, Bracchi M, Alagaratnam J, Lwanga J, Fox J, Winston A, Boffito M, Nelson M.

Brain Sci. 2019 Aug 9;9(8). pii: E195. doi: 10.3390/brainsci9080195.

4.

Pharmacokinetics (PK) of ethinylestradiol/levonorgestrel co-administered with atazanavir/cobicistat.

Elliot ER, Bisdomini E, Penchala SD, Khoo S, Nwokolo N, Boffito M.

HIV Res Clin Pract. 2019 Jul 23:1-10. doi: 10.1080/25787489.2019.1638077. [Epub ahead of print]

PMID:
31335301
5.

Evaluation of the psychometric properties of the HIV Disability Questionnaire among adults living with HIV in the United Kingdom: A cross-sectional self-report measurement study.

Brown DA, Simmons B, Boffito M, Aubry R, Nwokolo N, Harding R, O'Brien KK.

PLoS One. 2019 Jul 10;14(7):e0213222. doi: 10.1371/journal.pone.0213222. eCollection 2019.

6.

Validation of a Novel Multivariate Method of Defining HIV-Associated Cognitive Impairment.

Underwood J, De Francesco D, Cole JH, Caan MWA, van Zoest RA, Schmand BA, Sharp DJ, Sabin CA, Reiss P, Winston A; COmorBidity in Relation to AIDS (COBRA) Collaboration and the Pharmacokinetic and clinical Observations in PePle over fiftY (POPPY) Study Group .

Open Forum Infect Dis. 2019 May 3;6(6):ofz198. doi: 10.1093/ofid/ofz198. eCollection 2019 Jun.

7.

Risk factors and impact of patterns of co-occurring comorbidities in people living with HIV.

De Francesco D, Underwood J, Bagkeris E, Anderson J, Williams I, Vera JH, Post FA, Boffito M, Johnson M, Mallon PWG, Winston A, Sabin CA; Pharmacokinetic and Clinical Observations in PeoPle Over fiftY (POPPY) study.

AIDS. 2019 Oct 1;33(12):1871-1880. doi: 10.1097/QAD.0000000000002293.

PMID:
31259766
8.

Quantification of tenofovir disoproxil fumarate and emtricitabine in generic pre-exposure prophylaxis tablets obtained from the internet.

Wang X, Nutland W, Brady M, Green I, Boffito M, McClure M.

Int J STD AIDS. 2019 Jul;30(8):765-768. doi: 10.1177/0956462419841144. Epub 2019 May 9. No abstract available.

PMID:
31072205
9.

Pharmacokinetics of dolutegravir 100 mg once daily with rifampicin.

Wang X, Cerrone M, Ferretti F, Castrillo N, Maartens G, McClure M, Boffito M.

Int J Antimicrob Agents. 2019 Aug;54(2):202-206. doi: 10.1016/j.ijantimicag.2019.04.009. Epub 2019 Apr 16.

PMID:
31002950
10.

Guidelines in the context of medical ethics.

Waters LJ, Collins S, Boffito M.

BMJ. 2019 Mar 12;364:l1040. doi: 10.1136/bmj.l1040. No abstract available.

PMID:
30862691
11.

Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide.

Cerrone M, Alfarisi O, Neary M, Marzinke MA, Parsons TL, Owen A, Maartens G, Pozniak A, Flexner C, Boffito M.

J Antimicrob Chemother. 2019 Jun 1;74(6):1670-1678. doi: 10.1093/jac/dkz068.

PMID:
30815689
12.

A Lower Dose of Efavirenz Can Be Coadministered With Rifampicin and Isoniazid in Tuberculosis Patients.

Kaboggoza JP, Wang X, Neary M, Ayuso P, Sekaggya-Wiltshire C, Nakalema S, Owen A, McClure M, Lamorde M, Boffito M.

Open Forum Infect Dis. 2019 Jan 16;6(2):ofz035. doi: 10.1093/ofid/ofz035. eCollection 2019 Feb. No abstract available.

13.

Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers.

Elliot ER, Cerrone M, Challenger E, Else L, Amara A, Bisdomini E, Khoo S, Owen A, Boffito M.

J Antimicrob Chemother. 2019 May 1;74(5):1466. doi: 10.1093/jac/dky571. No abstract available.

PMID:
30778557
14.

Polypharmacy and drug-drug interactions in older and younger people living with HIV: the POPPY study.

Halloran MO, Boyle C, Kehoe B, Bagkeris E, Mallon P, Post FA, Vera J, Williams I, Anderson J, Winston A, Sachikonye M, Sabin C, Boffito M.

Antivir Ther. 2019;24(3):193-201. doi: 10.3851/IMP3293.

PMID:
30700636
15.

Pharmacological impact of antiretroviral therapy on platelet function to investigate human immunodeficiency virus-associated cardiovascular risk.

Taylor KA, Smyth E, Rauzi F, Cerrone M, Khawaja AA, Gazzard B, Nelson M, Boffito M, Emerson M.

Br J Pharmacol. 2019 Apr;176(7):879-889. doi: 10.1111/bph.14589. Epub 2019 Mar 14.

PMID:
30681136
16.

Magnetic Resonance Imaging of Cerebral Small Vessel Disease in Men Living with HIV and HIV-Negative Men Aged 50 and Above.

Haddow LJ, Sudre CH, Sokolska M, Gilson RC, Williams IG, Golay X, Ourselin S, Winston A, Sabin CA, Cardoso MJ, J├Ąger HR; Pharmacokinetics and clinical Observations in PeoPle over fiftY (POPPY) Study Group.

AIDS Res Hum Retroviruses. 2019 May;35(5):453-460. doi: 10.1089/AID.2018.0249. Epub 2019 Feb 20.

PMID:
30667282
17.

Patterns of Co-occurring Comorbidities in People Living With HIV.

De Francesco D, Verboeket SO, Underwood J, Bagkeris E, Wit FW, Mallon PWG, Winston A, Reiss P, Sabin CA; Pharmacokinetic and Clinical Observations in PeoPle Over fiftY (POPPY) study and the AGEhIV Cohort Study.

Open Forum Infect Dis. 2018 Oct 24;5(11):ofy272. doi: 10.1093/ofid/ofy272. eCollection 2018 Nov.

18.

Pain in people living with HIV and its association with healthcare resource use, well being and functional status.

Sabin CA, Harding R, Bagkeris E, Nkhoma K, Post FA, Sachikonye M, Boffito M, Anderson J, Mallon PWG, Williams I, Vera J, Johnson M, Babalis D, Winston A.

AIDS. 2018 Nov 28;32(18):2697-2706. doi: 10.1097/QAD.0000000000002021.

PMID:
30289809
19.

Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers.

Elliot ER, Cerrone M, Else L, Amara A, Bisdomini E, Khoo S, Owen A, Boffito M.

J Antimicrob Chemother. 2019 Jan 1;74(1):149-156. doi: 10.1093/jac/dky384.

PMID:
30272231
20.

Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Efavirenz 400 mg Once Daily During Pregnancy and Post-Partum.

Lamorde M, Wang X, Neary M, Bisdomini E, Nakalema S, Byakika-Kibwika P, Mukonzo JK, Khan W, Owen A, McClure M, Boffito M.

Clin Infect Dis. 2018 Aug 16;67(5):785-790. doi: 10.1093/cid/ciy161.

Supplemental Content

Loading ...
Support Center